AWM
CRSP icon

Abound Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Abound Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.82K Hold
125
– – ﹤0.01% 543
2026
Q1 		$5.95K Hold
125
– – ﹤0.01% 693
2025
Q4 		$6.55K Sell
125
-9
-7% -$539 ﹤0.01% 603
2025
Q3 		$8.69K Buy
134
+9
+7% +$517 ﹤0.01% 520
2025
Q2 		$6.08K Hold
125
– – ﹤0.01% 532
2025
Q1 		$4.25K Hold
125
– – ﹤0.01% 572
2024
Q4 		$4.92K Hold
125
– – ﹤0.01% 531
2024
Q3 		$5.87K Sell
125
-18
-13% -$913 ﹤0.01% 516
2024
Q2 		$7.72K Hold
143
– – ﹤0.01% 410
2024
Q1 		$9.75K Hold
143
– – ﹤0.01% 381
2023
Q4 		$8.95K Buy
143
+18
+14% +$995 ﹤0.01% 392
2023
Q3 		$5.67K Hold
125
– – ﹤0.01% 437
2023
Q2 		$7.02K Hold
125
– – ﹤0.01% 407
2023
Q1 		$5.65K Hold
125
– – ﹤0.01% 381
2022
Q4 		$5.08K Hold
125
– – ﹤0.01% 352
2022
Q3 		$8.17K Buy
+125
New +$9.06K ﹤0.01% 293

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Abound Wealth Management's CRSP Position: Q2 2026 in Review

Abound Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 125 shares worth $6.82K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Abound Wealth Management first reported a position in CRSP in Q3 2022 and has held it in 16 quarters since. The position peaked at $9.75K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Abound Wealth Management held 125 shares of CRISPR Therapeutics worth $6.82K as of Q2 2026.
  • Abound Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #543 holding.
  • Abound Wealth Management first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's CRISPR Therapeutics position peaked at $9.75K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.